9 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 14 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 9, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Infectious Disease: new trials by email Literature Review of Infectious Disease trials Research Report on Infectious Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV JCXH-108, Placebo - Respiratory Syncytial Virus (RSV), Infectious Disease | Phase 1 | Active not recruiting | Immorna Biotherapeutics, Inc. | 75 | 2024-09-25 | 2026-11-05 |
| A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel Azithromycin Oleogel (Oral and Rectal) - Infectious Disease, Drug Effect | Phase 1 | Completed | Brigham and Women's Hospital | 18 | 2024-08-08 | 2026-02-04 |
| Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers favipiravir, Placebo - Infectious Disease, Pharmacology | Phase 1 | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 39 | 2024-05-14 | 2026-02-12 |
| Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects RQ-001, Placebo - COVID-19, Infectious Disease | Phase 1 | Completed | Red Queen Therapeutics, Inc. | 66 | 2023-09-27 | 2024-01-11 |
| A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine JCXH-105, Active Control (Shingrix) - Herpes Zoster (HZ), Shingles | Phase 1 | Completed | Immorna Biotherapeutics, Inc. | 75 | 2023-05-26 | 2024-09-19 |
| Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals RVM-V001 30 µg, RVM-V002 30 µg, RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration - Infectious Disease, COVID-19 | Phase 1 / Phase 2 | Terminated | RVAC Medicines (US), Inc. | 24 | 2023-03-22 | 2023-10-16 |
| A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine JCXH-221, Placebo - COVID-19, Infectious Disease | Phase 1 | Completed | Immorna Biotherapeutics, Inc. | 73 | 2023-03-07 | 2024-09-19 |
| Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects 101-PGC-005 - Glucocorticoids Toxicity, COVID-19 | Phase 1 | Unknown | 101 Therapeutics | 6 | 2022-10-29 | 2022-12-14 |
| Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg - Infectious Disease, COVID-19 | Phase 1 | Terminated | RVAC Medicines (US), Inc. | 13 | 2022-09-12 | 2023-06-27 |
| A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants Acalabrutinib, Rabeprazole - Infectious Disease | Phase 1 | Completed | AstraZeneca | 35 | 2020-07-20 | 2020-10-30 |
| A Study in Healthy Volunteers CRV431, Placebo, TDF - Hepatitis B, Infectious Disease | Phase 1 | Completed | Hepion Pharmaceuticals, Inc. | 92 | 2019-07-09 | 2021-12-01 |
| A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects CMX157, placebo - Infectious Disease | Phase 1 | Completed | ContraVir Pharmaceuticals, Inc. | 50 | 2016-04-01 | 2017-02-02 |
| Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients P128-0.1 mg, P128-0.3 mg, P128-1.0 mg - Infectious Disease, Bacterial Infections | Phase 1 / Phase 2 | Completed | GangaGen, Inc. | 74 | 2012-12-01 | 2016-03-07 |
| A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005) MK-7655, Imipenem + Cilastatin, Caffeine - Infectious Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 49 | 2011-01-28 | 2020-06-11 |
Communicable Diseases (14) · COVID-19 (5) · Bacterial Infections (1) · Hepatitis B (1) · Herpes Zoster (1) · Liver Diseases (1) · Virus Diseases (1)
Disease Attributes (14) · Infections (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Virus Diseases (6) · Coronaviridae Infections (5) · Coronavirus Infections (5) · Lung Diseases (5) · Nidovirales Infections (5) · Pneumonia (5) · Pneumonia, Viral (5) · RNA Virus Infections (5) · Respiratory Tract Diseases (5) · Respiratory Tract Infections (5) · DNA Virus Infections (2)
RVM-V001 COVID-19 vaccine (2) · Administration, Rectal (1) · CRV-431 (1) · Caffeine (1) · Cilastatin, Imipenem Drug Combination (1) · Midazolam (1) · Omeprazole (1) · Rabeprazole (1) · acalabrutinib (1) · favipiravir (1) · hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine (1) · relebactam (1)
Immorna Biotherapeutics, Inc. (3) · RVAC Medicines (US), Inc. (2) · 101 Therapeutics (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · ContraVir Pharmaceuticals, Inc. (1) · GangaGen, Inc. (1) · Hepion Pharmaceuticals, Inc. (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Merck Sharp & Dohme LLC (1) · Red Queen Therapeutics, Inc. (1)
United States (7) · Singapore (2) · Australia (1) · France (1) · India (1) · Thailand (1)
Dale A Fisher, MBBS, FRACP (1) · Jill Greytok (1) · John Sullivan-Bolyai, MD, MPH (1) · Paul Eisenberg, MD, MPH (1) · Peter J. Winkle, MD FACP FACG CPI (1) · Surinder Kher, MD (1)